Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer
- 1 December 2003
- Vol. 62, 2-8
- https://doi.org/10.1016/j.urology.2003.09.009
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMYUrologic Clinics of North America, 2001
- Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1999
- RECURRENCE PATTERNS AFTER RADICAL RETROPUBIC PROSTATECTOMY: CLINICAL USEFULNESS OF PROSTATE SPECIFIC ANTIGEN DOUBLING TIMES AND LOG SLOPE PROSTATE SPECIFIC ANTIGENJournal of Urology, 1997
- Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancerRadiotherapy and Oncology, 1997
- Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: Correlation with histologic characteristics of the primary cancerUrology, 1997
- The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical ProstatectomyJournal of Urology, 1994
- Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancerCancer, 1994
- Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasesUrology, 1994
- Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancerCancer, 1993